Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.

Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

Abstract: 2-[(4-Benzyl)-1-piperidinyl)-methyl]benzimidazole-5-ol derivatives are NMDA NR2B receptor antagonists useful in the treatment of pain and other NMDA mediated diseases.

Abstract: Provided are a method, system, and program for handling a fabric failure. A module intercepts a signal indicating a failure of a path in a fabric providing a connection to a shared device. The module generates an interrupt to a device driver in an operating system providing an interface to the shared device that is inaccessible due to the path failure. The device driver requests information from the module on a status of a plurality of devices that are not accessible due to the path failure and receives information indicating the inaccessible device. The device driver reconfigures to discontinue use of the inaccessible device.

Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

Abstract: Provided are a method, system and article of manufacture, wherein a first application executes at least two threads corresponding to a simultaneous multi-threaded processor whose resources have been acquired by the first application. The at least two threads are synchronized before releasing the simultaneous multi-threaded processor to a second application.

Abstract: Provided are a method, system and program for processing complexes to access shared devices. A lock to a plurality of shared devices is maintained and accessible to a first and second processing systems. The first processing complex determines a first delay time and the second processing complex determines a second delay time. The first processing complex issues a request for the lock in response to expiration of the first delay time and the second processing complex issues a request for the lock in response to expiration of the second delay time.

Abstract: A technique for handling hardware errors in a computing system, such as a data storage facility, while avoiding a system crash. An interface is registered with an operating system of the computing system to process hardware errors. When a hardware error is detected, the interface checks an error register to identify the adapter that likely causes the error, and quarantines, e.g., blocks off, the offending adapter from the computing system. The interface then notifies the operating system that the error has been handled, thereby causing the operating system to bypass a system crash that would otherwise occur. The interface can be provided as a kernel extension of a device driver associated with the operating system.

Abstract: Provided are a method, system, and program for configuring shared devices over a fabric. A module in a first processing complex configures a first part of a fabric enabling communication with a set of devices accessible through the first part of the fabric. The module detects a located device accessible through a second part of the fabric, wherein a second processing complex is designated to configure the second part of the fabric and the located device. The module determines whether the second processing complex is available in response to detecting the uninitialized device. The module passes to a device driver in the first processing complex an uninitialized property for the located device. The device driver requests the module to configure the second part of the fabric to enable access to the located device over the second part of the fabric in response to determining that the located device has the uninitialized property.

Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

Abstract: Load-bearing devices, each including an overload indicator of the present invention interconnecting load bearing connectors, preferably elongated load bearing connectors are provided. In preferred embodiments, the load bearing connectors are chains, ropes, wire ropes, cables, straps and the like, preferably chain. The wire form overload indicator preferably includes a modified wire form link, preferably either a modified welded link or a modified quick link, generally having a first thickness and first and second elongated sides. The modified link preferably includes two elongated sides, one of which preferably has a portion having a diminished thickness narrower than the first thickness. The diminished thickness preferably has a generally predetermined load bearing capacity or capability and is calibrated to reduce the load bearing capacity or capability of the overload indicator.

Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B in antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

Abstract: Provided are a method, system, and article of manufacture, wherein in certain embodiments a determination is made as to whether a configuration indicator associated with a resource indicates a delayed configuration of the resource, wherein the resource is shared by a plurality of processing complexes via a bus, and wherein if the delayed configuration of the resource is indicated then the resource is prevented from being configured during initial program loads of the plurality of processing complexes. The resource is configured by only one of the of plurality of processing complexes that shares the resource, in response to determining that the configuration indicator associated with the resource indicates the delayed configuration of the resource.

Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

Abstract: Provided are a method, system, and article of manufacture, wherein in certain embodiments, a plurality of logical memory blocks corresponding to a memory in a computational device are allocated. An attribute is associated with at least one logical memory block, wherein the attribute indicates whether the at least one logical memory block can be swapped from the memory, and wherein physical blocks corresponding to the at least one logical memory block are contiguous.

Abstract: Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R1, R2, R3, R4 and R5 are any of a number of groups as defined in the specification, A and D are as defined in the specification, and pharmaceutical compositions and methods of treatment utilising such compounds.

Abstract: Provided herein is a compound having the formula (I), (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of a heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

Abstract: Provided herein is a compound having the formula (I) (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of q heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.